Colorectal
Featured Articles
(Bayer) July 18, 2019 - Bayer, Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer's kinase inhibitor Stivarga® (regorafenib) and Bristol-Myers Squibb's / Ono's anti-PD-1 immune checkpoint inhibitor,...
Read Article
(ESMO World GI 2019) July 6, 2019 - Medical oncologists administer anticancer drug regorafenib to try to improve overall survival in patients with metastatic colorectal cancer who have ceased to respond to standard therapy (known as refractory mCRC). However, some of the adverse events related to the use of this drug often limits its...
Read Article
Latest Articles
July 18, 2019
July 15, 2019
July 11, 2019
July 11, 2019
July 09, 2019
July 09, 2019
July 08, 2019
July 08, 2019
View More
News Commentary
Editor Image
22 May, 2019 | by Howard S. Hochster, MD
In a long expected result, the 2nd-3rd line BEACON trial of encorafenib and...
View Comment
View More
OBR Green
There are no Colorectal OBR Green articles.
OBR Blog
There are no Colorectal blog entries.